Rose Sharon Shabet's Net Worth

$2.08 Billion

Estimate Recalculated Mar 1, 2024 09:02PM EST

Who is Rose Sharon Shabet?

Rose Sharon Shabet has an estimated net worth of $2.08 Billion. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, Inc., RayzeBio, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Gene Therapies Ltd., Rallybio Corp, and Frazier Lifesciences Acquisition Corp.

SEC CIK

Rose Sharon Shabet's CIK is 0001711393

Past Insider Trading and Trends

2019 was Rose Sharon Shabet's most active year for acquiring shares with 72 total transactions. Rose Sharon Shabet's most active month to acquire stocks was the month of May. 2022 was Rose Sharon Shabet's most active year for disposing of shares, totalling 22 transactions. Rose Sharon Shabet's most active month to dispose stocks was the month of August. 2022 saw Rose Sharon Shabet paying a total of $312,238,236.29 for 300,884,319 shares, this is the most they've acquired in one year. In 2020 Rose Sharon Shabet cashed out on 19,163,712 shares for a total of $573,887,078.58, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $15.51

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-10.26%
-1.40M
$29.80
-$41,719,639.31
12.24M
Sep 8 - Sep 9
Form 4
7.17M
$19.00
$43,700,000.00
7.17M
Jan 11 - Nov 11
Form 3
0
0
No matching records found

Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.83

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-3.23%
-1.00M
$55.65
-$55,650,000.00
29.99M
Dec 14
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 3
0
0
Form 3
0
0
No matching records found

Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.35

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.25%
-500.00K
$50.50
-$25,250,000.00
3.94M
Dec 1
Form 4
+19.50%
725K
$18.00
$13,050,000.00
4.44M
Apr 7
Form 3
0
0
No matching records found

RayzeBio, Inc. (RYZB) Snapshot price: $62.18

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-6.64M
0
Feb 26
Form 4
-100.00%
-6.64M
0
Feb 26
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 3
0
0
Form 3
0
0
No matching records found

Inhibrx, Inc. (INBX) Snapshot price: $38.94

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
511.63K
$19.35
$9,899,982.45
511.63K
Aug 28
Form 4
+93.42%
1.33M
$30.00
$39,999,856.67
2.76M
Oct 7
Form 4
+14.45%
180.22K
$18.92
$3,409,865.52
1.43M
Aug 26
Form 4
+11.78%
131.47K
$19.39
$2,548,687.94
1.25M
Aug 24 - Aug 25
Form 3
0
0
No matching records found